REVEAL GENOMICS® develops the HER2DX® genomic test, which analyzes complex genomic and clinical data to identify biomarkers in HER2+ breast cancer patients. This technology enables healthcare providers to select optimal treatment strategies, improving patient outcomes through personalized therapy decisions.
Funding
$6.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Selecting the optimal treatment strategy for HER2-positive breast cancer patients is challenging due to the complex interplay of genomic and clinical factors. Traditional methods may not fully capture the heterogeneity of the disease, potentially leading to suboptimal treatment decisions and patient outcomes.
Solution
REVEAL GENOMICS® offers HER2DX®, a genomic test designed to analyze complex genomic and clinical data to identify relevant biomarkers in HER2-positive breast cancer. This technology aims to provide healthcare providers with a more comprehensive understanding of each patient's unique disease profile. By decoding biomarkers before, during, or after therapies, HER2DX® seeks to reveal innovative insights that can inform personalized treatment strategies. The test results are presented in an easy-to-interpret format, facilitating clinical decision-making.
Target Audience
The primary audience includes oncologists, pathologists, and other healthcare professionals involved in the diagnosis and treatment of HER2-positive breast cancer.
Features
- Analyzes complex genomic and clinical data to identify biomarkers in HER2-positive breast cancer.
- Provides scores represented with their scale for visual results.
- Offers extensive description and guidance for reading the results, their clinical significance, and supporting data.
- Delivers an extensive explanation of the scores for improved interpretation of the results.